RE:1A Results/Market AwarenessI wish you were right but the fact is Promis over the last couple of years has just been testing animals and humans not alzheimers patients. Numerous companies have passed phase 1 safety results testing healthy and alzheimers patients. These have never been market movers. Acumenpharma seemed to have positive results with maybe the lowest aria to date did not move their stock price.
The same with Prothena not much info on that front except their stock price has fallen from $80 to $20. Promis does not have the organizational capacity to proceed in testing alzheimers patients. The need a deal of some kind like Prothena struck with Brystol Myers starting with 80 million in2021 another 55 million last summer.
Prothena will have received a total of $230 million pursuant to the collaboration, and is eligible to receive up to an additional $160 million for U.S. rights, up to $165 million for global rights,be and up to $1.7 billion for regulatory and commercial milestone payments for a total of up to $2.2 billion plus potential tiered commercial sales royalties across multiple programs.